7 news items
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
ALLO
23 May 24
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
ALLO
13 May 24
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
ALLO
13 May 24
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
ALLO
6 May 24
-Looking Statements for AllogeneThis press release contains forward-looking statements for purposes of the safe harbor provisions
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
ALLO
26 Apr 24
release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
0gmadbdmzih2c8d4pr75d6yo6h07n5ohwhngafvcvql
ALLO
12 Mar 24
release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995
2xue4zn8ib6m93nv37304zu5skzt38cud cntlccm8qz0a6e
ALLO
5 Mar 24
statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include
- Prev
- 1
- Next